Advances of Nano-Structured Extended-Release Local Anesthetics

He, Yumiao; Qin, Linan; Huang, Yuguang; Ma, Chao

doi:10.1186/s11671-019-3241-2

Cited by 41 publications

(28 citation statements)

References 166 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DepoFoam™ technology is also utilized to tackle pain management before and after surgical procedure. Exparel® (bupivacaine liposome), approved by FDA in 2011, is a longer acting form of traditional bupivacaine 105 . Day et al.…”

Section: Strategies To Manipulate the Drug Release From Delivery Systemsmentioning

confidence: 99%

A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives

Shi

Wang

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

The need for long-term treatments of chronic diseases has motivated the widespread development of long-acting parenteral formulations (LAPFs) with the aim of improving drug pharmacokinetics and therapeutic efficacy. LAPFs have been proven to extend the half-life of therapeutics, as well as to improve patient adherence; consequently, this enhances the outcome of therapy positively. Over past decades, considerable progress has been made in designing effective LAPFs in both preclinical and clinical settings. Here we review the latest advances of LAPFs in preclinical and clinical stages, focusing on the strategies and underlying mechanisms for achieving long acting. Existing strategies are classified into manipulation of in vivo clearance and manipulation of drug release from delivery systems, respectively. And the current challenges and prospects of each strategy are discussed. In addition, we also briefly discuss the design principles of LAPFs and provide future perspectives of the rational design of more effective LAPFs for their further clinical translation.

show abstract

Section: Strategies To Manipulate the Drug Release From Delivery Systemsmentioning

confidence: 99%

A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives

Shi

Wang

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…The component that was sensitive to the enzyme is the azo bond linked to the MSNs and chitosan. The results showed that the azo bond was broken in the presence of colon enzyme secreted by colonic microflora [ 179 ]. In another work, the same enzyme was used as a response to MSNs with guar gum as the pores’ cap.…”

Section: Msns As Smart Drug Delivery Agentmentioning

confidence: 99%

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Cancer treatment and therapy have made significant leaps and bounds in these past decades. However, there are still cases where surgical removal is impossible, metastases are challenging, and chemotherapy and radiotherapy pose severe side effects. Therefore, a need to find more effective and specific treatments still exists. One way is through the utilization of drug delivery agents (DDA) based on nanomaterials. In 2001, mesoporous silica nanoparticles (MSNs) were first used as DDA and have gained considerable attention in this field. The popularity of MSNs is due to their unique properties such as tunable particle and pore size, high surface area and pore volume, easy functionalization and surface modification, high stability and their capability to efficiently entrap cargo molecules. This review describes the latest advancement of MSNs as DDA for cancer treatment. We focus on the fabrication of MSNs, the challenges in DDA development and how MSNs address the problems through the development of smart DDA using MSNs. Besides that, MSNs have also been applied as a multifunctional DDA where they can serve in both the diagnostic and treatment of cancer. Overall, we argue MSNs provide a bright future for both the diagnosis and treatment of cancer.

show abstract

“…Exparel® was the first approved liposomal LA to combine racemic bupivacaine with liposomes. Polymersomes have advances over liposomes with complementary profiles, inspiring the emergence of hybrid carriers [35,36]. Also, multilamellar vesicles with ropivacaine are being investigated to prolong its analgesic effect [37].…”

Section: Amino Amide Lasmentioning

confidence: 99%

Local Anesthetics

Whizar-Lugo¹,

Íñiguez-López²,

Cárdenas-Maytorena³

et al. 2020

Topics in Local Anesthetics

View full text Add to dashboard Cite

The fascinating history of local anesthetics (LAs) began in South America with the herbal and traditional use of cocaine leaves by the indigenous peoples of Peru and Bolivia, the sacred plant of the Incas Erythroxylum coca. The use for anesthetic purposes dates back to 1884. Since then, the evolution of LAs has been closely related to research motivated by its efficacy and safety versus toxicity. According to their chemical structure, these drugs are classified into two main groups: esters and amino amides; however, there are three LAs with different characteristics: articaine, sameridine, and centbucridine. The pharmacological and toxic mode of action is primarily in the voltage-dependent sodium channels located in the cell membrane, which clinically produces analgesia, anesthesia, seizures, arrhythmias, and cardiac arrest. The quality of anesthesia and analgesia depends on the type of LA, dose, and application technique, while the deleterious effects are secondary to its plasma concentration. Nonanesthetic properties of LAs such as their antimicrobial, antineoplastic, antiarrhythmics, antitussive, and antiasthmatics effects have been described and are briefly reviewed.

show abstract

Advances of Nano-Structured Extended-Release Local Anesthetics

Cited by 41 publications

References 166 publications

A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives

A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

Local Anesthetics

Contact Info

Product

Resources

About